Skip to main content

Table 3 List of KDM genes significantly up- or down-regulated in PCa clinical subtypes (MSKCC and Oncomine databases)

From: The emerging role of histone lysine demethylases in prostate cancer

Gene Clinical Variable Gene expression P value Putative function Oncomine
KDM1B Overall Survival (OS) Higher predicts shorter OS 0.0045 Oncogene In agreement
KDM2B PSA level at diagnosis Higher predicts higher PSA 0.0070 Oncogene  
  Gleason Score Higher predicts higher grade 0.0001   
  Lymph Node invasion Higher predicts invasion 0.0002   
  Metastasis Higher predicts higher metastatic risk 3.09E-07   
  Recurrence-Free Survival (RFS) Higher predicts shorter RFS 0.0066   
KDM3B PSA level at diagnosis Lower predicts higher PSA 0.0004 Oncosuppressor In disagreement
  Gleason Score Lower predicts higher grade 0.0066   
KDM4C Metastasis Lower in non-metastatic tumors 0.0086 Oncogene In agreement
KDM4D Gleason Score Higher predicts higher grade 0.0002 Oncogene  
  Lymph Node invasion Higher predicts invasion 0.0019   
  Recurrence-Free Survival (RFS) Higher predicts shorter RFS 0.0002   
  Metastasis Lower in non-metastatic tumors 0.001   
KDM5A Probability of recurrence after prostatectomy Higher predicts higher probability 0.002 Oncogene  
KDM5D Gleason Score Higher predicts lower grade 0.0035 Oncosuppressor In agreement
  Lymph Node invasion Lower predict invasion 0.0036   
  Metastasis Lower predicts higher metastatic risk 3.7E-5   
  Probability of recurrence after prostatectomy Lower predicts higher probability 0.0003   
KDM7 Gleason Score Higher predicts higher grade 0.0016 ?  
  Lymph Node invasion Lower predicts invasion 0.0009   
  Recurrence-Free Survival (RFS) Higher predicts longer RFS 0.008   
  1. From the MSKCC database, we report all associations with p < 0.01, for the following clinical variables: PSA (prostate specific antigen) levels at diagnosis; Gleason score, based on prostatectomy; lymph node invasion; metastatic risk; recurrence free survival (or probability of recurrence) after prostatectomy; overall survival. Oncomine data are described as “in agreement” if they confirm the oncogene/oncosuppressor function deduced from the MSKCC database. Oncomine thresholds: p < 0.01; fold-change >2.0. Oncomine data are shown in Figure 2. For gene aliases, see Table 1.